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ABSTRACT  
Cyclophosphamide is a cytotoxic anti-tumor pro-drug belonging to the alkylating agents 
which is indicated for the treatment of many cancers as well as some immune-related 
disorders. In Spain, it is marketed as powder for injection and as sugar-coated tablets 
by Baxter Oncology. Cyclophosphamide is well absorbed from the gastrointestinal wall, 
with an oral bioavailability of 85-100%. This justifies the existence of an oral medication 
comprising the drug, like sugar-coated tablets. Cyclophosphamide structure is prone to 
undergo hydrolysis and other degradation reactions in aqueous solution, and is labile to 
high temperatures, changes in moisture levels, and light. Instability to the latter 
conditions might accelerate the degradation of the active ingredient during the 
manufacture of the drug product, and is one of the reasons for tablet coating. 
Accordingly, drug sensitivity to water and temperature are especially critical, since most 
manufacturing processes are carried out in aqueous medium and involve heating 
systems like hot air drying. Indeed, commercially available cyclophosphamide coated 
tablets are produced by means of a wet granulation process followed by coverage with 
the sugar-coating technique. Both of these methods are subjected to the use of water 
and to several drying stages, thus compromising the stability of the active ingredient. 
Hence, the main objective of this project has been to develop a novel formulation of 
cyclophosphamide coated tablets that minimized drug exposure to water and heat 
during the manufacturing process. As a result, sorbitol film-coated tablets have been 
proposed. These consist of a tablet core obtained by direct compression without the 
need of water, and a film-coating containing glycerol instead of water as the main 
coating solvent together with sorbitol as a plasticizer. 
RESUM 
La ciclofosfamida és un profàrmac antitumoral citotòxic pertanyent al grup dels agents 
alquilants que està indicat en el tractament de nombrosos càncers i algunes malalties 
del sistema immunitari. A Espanya es troba comercialitzada per Baxter Oncology en 
forma de pólvores per a solució injectable i com a dragees. La ciclofosfamida 
s’absorbeix bé al tracte gastrointestinal, presentant una biodisponibilitat d’entre el 85 i 
el 100%, la qual cosa justifica l’existència d’una forma farmacèutica d’administració 
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oral del fàrmac com són les dragees. L’estructura de la ciclofosfamida és propensa a 
patir hidròlisis i altres reaccions de degradació en solució aquosa, i és làbil a les altes 
temperatures, als canvis d’humitat i a la llum. La inestabilitat del fàrmac enfront a 
aquestes condicions podria accelerar la degradació del principi actiu durant la 
fabricació del medicament i és una de les raons per a recobrir els comprimits. En 
aquest sentit, la inestabilitat a l’aigua i a la temperatura són especialment crítiques, ja 
que la majoria de processos de fabricació es realitzen en medi aquós i impliquen 
l’escalfament del fàrmac per mitjà de sistemes com l’assecament amb aire calent. De 
fet, les dragees de ciclofosfamida disponibles al mercat es fabriquen a través d’un 
procés de granulació per via humida seguit de drageat o recobriment amb sacarosa. 
Aquests dos mètodes requereixen l’ús d’aigua i de varies etapes d’assecat, la qual 
cosa pot comprometre l’estabilitat del principi actiu. En conseqüència, el principal 
objectiu d’aquest treball ha estat desenvolupar una nova formulació de comprimits de 
ciclofosfamida recoberts que minimitzés l’exposició del fàrmac a l’aigua i la calor 
durant el procés de fabricació. Com a resultat, s’han proposat uns comprimits amb 
recobriment pel·licular de sorbitol. Aquests estan formats per un nucli obtingut per 
compressió directa sense necessitat d’aigua, i una cobertura pel·licular amb glicerol 
enlloc d’aigua com a solvent principal juntament amb sorbitol com a plastificant.  
INTEGRATION OF THE DIFFERENT FIELDS 
This work integrates several pharmaceutical disciplines. The main one is 
pharmaceutical technology, which is ubiquitous throughout the whole project and takes 
on especial relevance in the results/discussion section, where an existing 
pharmaceutical formulation is analyzed and a novel one is presented.  
In order to address the mentioned task as well as understand the reasons underlying 
the route of administration and the pharmaceutical formulation of the drug, prior 
attention is drawn to the physicochemical, biopharmaceutical and pharmacokinetic 
properties of the active ingredient. Hence, physical chemistry and biopharmacy and 
pharmacokinetics are important fields comprised in the project.  
On the other hand, history of pharmacy is tackled when reviewing the sugar-coating 
technique, a traditional coating process that dates back to the 1st century AD but has 
survived the passing of time.  
The structure of cyclophosphamide is also discussed, thus introducing some basic 
concepts of pharmaceutical chemistry. Finally, the introduction brings in several 
aspects of the drug related to the pharmacology and therapeutics area, such as the 
mechanism of action, the indications and the adverse effects.  
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1. INTRODUCTION 
1.1. What Is Cyclophosphamide? 
1.1.1. Indications 
Cyclophosphamide is an alkylating anti-tumor drug that 
shows anti-tumor activities against a broad range of cancers 
including Hodgkin’s disease and non-Hodgkin lymphoma, 
multiple myeloma, leukaemia, mycosis fungoides, 
neuroblastoma, carcinoma of the ovary, retinoblastoma, 
carcinoma of the breast[1][2][3], germinal tumors[1], small 
cell cancer of the lung[3], and sarcoma[3]. In the treatment of 
cancer it can also be used at low doses as either an anti-
angiogenic or an immune-stimulatory agent in combination 
with other immunotherapies[4].  
Cyclophosphamide is as well an immunosuppressive agent. Thus, it can prevent graft 
rejection after organ and bone marrow transplantation[1], and might be used in the 
treatment of autoimmune disorders[1][5], such as Wegener’s granulomatosis[5], 
rheumatoid arthritis[5], lupus erythematosus[5], and nephrotic syndrome[2][5].  
1.1.2. Mechanism of Action 
Cyclophosphamide is a cytotoxic alkylating agent which exerts its mechanism by 
forming covalent bonds between its alkyl groups and different nucleophilic molecules in 
cells. Although many cellular entities are alkylated by the drug, its interaction with DNA, 
known as DNA cross-linking, is the most important one in relation to anti-tumor activity. 
Cyclophosphamide action is said to be cell cycle nonspecific, since it can react with 
cells at any time. Nevertheless, due to the fact that nucleotides are more likely to be 
alkylated during the replication process, alkylation is more effective against rapidly 
proliferating (in cycle) cells than against non-cycling cells[5]. 
Figure 1. Cyclophosphamide  
Structure. 
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The cross-linking effect applies not only for cancer cells, but also for overactive 
immune competent cells that are found in various autoimmune diseases. Indeed, 
cyclophosphamide is an effective inhibitor of cell mediated immune response, it leads 
to a depletion of lymphocytes in the peripheral blood and tissue, and it affects 
monocyte function leading to a decrease in IL-1 and TNF production[6].  
Metabolic Activation 
Cyclophosphamide is a pro-drug, so, in order to exhibit its anti-tumor activity, it has to 
be converted to its active metabolite. This conversion takes place mainly in the liver by 
the enzymes of the mixed function oxidase system (cytochrome P450 enzyme system, 
CYP450), specially CYP450 2B. The first step in this activation involves the ring 
hydroxylation of cyclophosphamide to yield 4-hydroxycyclophosphamide, which is 
spontaneously converted to phosphoramide mustard and acrolein once in cells.  
Phosphoramide mustard is a bifunctional alkylating metabolite responsible for the 
biologic activity, whereas acrolein is the main toxic metabolite of cyclophosphamide. 
Thereby, phosphoramide mustard produces multiple monofunctional and bifunctional 
adducts with guanine. A part from phosphoramide, there are other metabolites involved 
in the cross-linking process, like nornitrogen mustard (a carboxyphosphamide 
metabolite) and acrolein itself[5].  
DNA Alkylation 
The bisclhorethylamino group of phosphoramide mustard bound to a tertiary nitrogen is 
responsible for the biologic activity. In the first step, one of the chlorides of the drug is 
lost and the beta carbon reacts with the nucleophilic nitrogen to form a cyclic, positive 
charged and very reactive aziridine molecule. The second step is characterized by the 
formation of the primary alkylating product, as a result of the reaction between the 
aziridium ring and a nucleophilic group in the DNA molecule (usually the N7 position of 
guanine). This process is repeated when the second chloroethyl group of the molecule 
losses its chloride, generating once again an aziridine electrophyl radical that will 
alkylate another nitrogen base. The overall reaction can take place sequentially thanks 
to the bifunctional alkylating character of the drug, which allows it to react with the N7 
groups of two different guanine residues. This is evidenced by a covalent cross-linking 
between two alkylated nucleophilic groups in the same DNA chain or between the two 
strands of the double helix[5]. 
 
 
 
 
Figure 2. DNA alkylation 
mediated by 
mechlorethamine, an 
alkylating agent similar to 
cyclophosphamide.  
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Consequences of DNA Alkylation  
In the guanine adduct, the iminol tautomer is favored. This changes the base-pairing 
preference from cytosine to thymine, causing mutations during DNA replication and 
other alterations which ultimately result in inhibition of the replication process and cell 
death by apoptosis. Although the specific cause of cell death induced by 
cyclophosphamide is not yet well known, mechanisms that lead to apoptosis, like p53, 
may be activated in response to DNA alteration[5].  
1.1.3. Adverse Effects and Contraindications 
Cyclophosphamide mechanism of action is associated with many severe adverse 
effects which may require dose monitoring, dose reduction or even discontinuation of 
treatment[6].    
Like most cytotoxic drugs, cyclophosphamide can cause myelosupression (leukopenia, 
neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe 
immunosuppression which may lead to serious infections. On the other hand, the 
genotoxic and mutagenic character of the drug can give rise to male and female 
infertility, while embryo-fetal toxicity or teratogenicity of the embryo or fetus may be 
seen if it is administered to a pregnant woman. Hemorrhagic cystitis and secondary 
bladder cancer, as well as other forms of urinary and renal toxicity, have also been 
reported. Other possible side effects of cyclophosphamide are cardial toxicity, 
pulmonary toxicity, secondary malignancies, veno-occlusive liver disease (VOD), 
impairment of wound healing, hyponatremia, anaphylactic reactions, nausea and 
vomiting, and alopecia[2].   
Cyclophosphamide is contraindicated in patients with a history of severe 
hypersensitivity reactions to it, and in urinary outflow obstruction. Patients with severe 
renal impairment should be monitored, since decreased renal excretion may result in 
increased plasma levels of the drug and its metabolites, leading to increased toxicity. In 
addition, pregnancy and nursing should be avoided during treatment with 
cyclophosphamide, and female and male patients of reproductive potential should use 
contraception after completion of treatment[2].  
1.1.4. Methods of Administration and Dosages 
Cyclophosphamide is administered orally or by intravenous injection or infusion in 
several different dosage regimens[2].  
In patients with malignant diseases receiving cyclophosphamide monotherapy, 
induction therapy is usually initiated with an intravenous cyclophosphamide loading 
dose of 40–50 mg/kg administered in divided doses over 2–5 days, whereas the usual 
oral dose for induction or maintenance therapy is 1–5 mg/kg daily. These doses must 
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be adjusted in accord with evidence of antitumor activity and/or leukopenia and may be 
reduced in combination with other cytotoxic agents[2].  
In the treatment of inflammatory rheumatic diseases, lower intravenous (e.g. 15 mg/kg 
every 2-3 weeks) or oral doses (e.g. 2 mg/kg/day) are used[6], while in patients who 
undergo transplantation cyclophosphamide can be given in very high doses (e.g. 60 
mg/kg for two days)[3]. 
1.2. In What Dosage Forms is Cyclophosphamide 
Currently Marketed? 
Cyclophosphamide is used in most countries around the world, where it is marketed by 
several laboratories in different dosage forms and strengths. In this project, attention 
has been drawn to the cyclophosphamide medications that are currently 
commercialized in Spain, on the one hand, and in the United States of America, on the 
other.  
1.2.1. Dosage Forms Marketed in Spain 
In Spain, two dosage forms of cyclophosphamide are currently available under 
prescription[7]: 
– Powder for solution for injection: Marketed by Baxter Oncology under the brand 
name Genoxal® in two different doses (200 mg/vial and 1 g/vial).  
– Coated Tablets: Marketed by Baxter Oncology under the brand name Genoxal® 
in a dose of 50 mg. 
1.2.2. Dosage Forms Marketed in The United States of America 
In contrast, in the United States, coated tablets have been recently withdrawn by the 
marketing authorization holder and replaced by cyclophosphamide capsules, which 
have the same composition and indications as those of the prior commercialized oral 
form[8]. In addition, lyophilized powder for injection has been introduced. Overall, 
currently marketed forms of cyclophosphamide in the USA are[9]:  
– Powder for solution for injection: Marketed as a generic drug by Sandoz in 
collaboration with Jiangsu Hengrui Med[10] (the owner of the Abbreviated New 
Drug Application (ANDA)) and by Baxter Healthcare. In both cases, the drug is 
accessible in three doses (500 mg/vial, 1 g/vial and 2 g/vial).  
– Lyophilized powder for solution for injection: Marketed by Baxter Healthcare 
under the brand name Cytoxan® in three doses (500 mg/vial, 1 g/vial and 2 
g/vial).  
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– Capsules: Marketed as a generic drug by Roxane in two available doses (25 mg 
and 50 mg). 
1.2.3. Overview of Cyclophosphamide Medications Available in Spain 
and in The United States 
PRODUCT STRENGTH EXCIPIENTS 
Genoxal grageas
®
 (Baxter Oncology)  50 mg 
Tablet core: Maize starch, lactose 
monohydrate, calcium hydrogen 
phosphate dihydrate, talc, 
magnesium stearate, gelatine, 
glycerol (85%) 
Coating: Sucrose, titanium dioxide, 
calcium carbonate, talc, macrogol 
35000, silica colloidal anhydrous, 
povidone, sodium 
carboxymethylcellulose, polysorbate 
20, montan glycol wax, FD&C Blue 
No 1, D&C Yellow No. 10 aluminum 
lake 
Cyclophosphamide capsules 
(Roxane Laboratories)  
25 mg 
50 mg 
Capsule: Pregelatinized starch and 
sodium stearyl fumarate 
Capsule shell: FD&C Blue No 1, 
FD&C Red No 40, gelatin and 
titanium dioxide 
Genoxal inyectable
®
 (Baxter 
Oncology) 
200 mg/vial 
1 mg/vial 
None 
Cyclophosphamide for injection 
(Baxter Oncology)  
500 mg/vial 
1 g/vial 
2 g/vial 
None 
Cyclophosphamide for injection 
(Jiangsu hengrui med – Sandoz) 
500 mg/vial 
1 g/vial 
2 g/vial 
None 
Cytoxan
®
 (Liophylized)  
500 mg/vial 
1 g/vial 
2 g/vial 
Mannitol 
Table 1. List of cyclophosphamide medications available in Spain and in the USA (different doses and 
excipients are detailed for each medication).[9][7] 
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2. OBJECTIVES 
The objectives of this work are the following: 
– Study cyclophosphamide focusing on its structure, physicochemical properties, 
stability, pharmacokinetics, and other aspects which condition the route of 
administration and the dosage form in which is delivered. 
– Review the traditional sugar-coating technique and introduce some of the 
changes that it has faced over time. 
– Justify oral administration of cyclophosphamide and underline the advantages 
of coated tablets in comparison with other oral forms in which the drug can be 
encountered.  
–  Analyze currently commercially available cyclophosphamide sugar-coated 
tablets in terms of pharmaceutical technology.  
– Propose a novel formulation of cyclophosphamide coated tablets. 
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3. MATERIAL AND METHODS 
The sources referred in this book are a combination of summaries of product 
characteristics, research papers, reviews, books, and websites.  
The summary of product characteristics of Genoxal Grageas was not available at CIMA 
(Centro de Información Online de Medicamentos de la Agencia Epañola de 
Medicamentos y Productos Sanitarios), so the equivalent ones from the United States 
of America and from the United Kingdom have been used. These documents have 
been obtained from the FDA (Food and Drug Administration) and the Electronic 
Medicines Compendium (eMC) websites, respectively, and have been key to introduce 
the most relevant aspects of the medication and to find out the different excipients 
comprising currently commercialized cyclophosphamide coated tablets.     
Most articles and reviews have been found through Scifinder, a database of chemical 
and bibliographic information that allows to make searches by keyword and to select 
the most interesting information. Then, if possible, they have been downloaded from 
online libraries and databases like Springer or Pubmed, or partially consulted online in 
case of restriction. Research papers and reviews have been especially important to 
outline the pharmacokinetics of the active ingredient, as well as to justify both the route 
of administration and the dosage form of cyclophosphamide sugar-coated tablets.  
To describe the traditional sugar-coating process, some books have been borrowed 
from the library of pharmacy. On the other hand, the Handbook of Pharmaceutical 
Excipients consulted online through CRAI (Centre de Recursos per a l'Aprenentatge i 
la Investigació) has been the main information source when reviewing the formulation 
of cyclophosphamide sugar-coated tablets and when choosing the excipients of the 
novel sorbitol film-coated formulation. 
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4. DEVELOPMENT OF THE  
PROJECT 
4.1. Important Cyclophosphamide Properties Regarding  
Pharmaceutical Formulation 
4.1.1. Structural Properties 
Cyclophosphamide, an organic compound with 
chemical name 2-[bis(2 
chloroethyl)amino]tetrahydro-2H-1,3,2-
oxazaphosphorine 2-oxide and the molecular 
formula C7H15Cl2N2O2P, is a tertiary amine which 
belongs to the nitrogen mustard compounds. These 
are compounds that have two beta-haloalkyl groups 
bound to a phosphorus atom[11].  
Several substituents can be found in the cyclophosphamide structure: 
Phosphorodiamide, phosphoric acid ester, oxazaphosphinane, polyamine, 
organochloride, and alkyl halide, approaching the substance to many alternative 
chemical parents[11].   
The presence of an asimetric phosphorus atom in the structure of cyclophosphamide is 
the feature that explains its chirality. This results in two enantiomers, R-(+)-
cyclophosphamide, and S-(−)-cyclophosphamide, which have the same structure but 
different configuration and thus are not interchangeable[12]. In spite of this, the racemic 
mixture of S-(−)- R-(+)-cyclophosphamide enantiomers is the one usually used in the 
clinical practice, although preclinical data show that S-(−)-cyclophosphamide exhibits a 
greater antitumor effect than the R-(+)-enantiomer[12][13].  
Cyclophosphamide can be found in its anhydrous form or as cyclophosphamide 
monohydrate. The last one contains a single molecule of water of crystallization per 
molecule of drug substance and is the most stable form of the drug. Thus, it is usually 
Figure 3. Cyclophosphamide monohydrate 
with its asimetric phosphorus.  
*
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the one used to manufacture both oral and intravenous cyclophosphamide 
preparations.  
4.1.2. Physicochemical Properties 
Physical and chemical properties of cyclophosphamide monohydrate, referred to as 
cyclophosphamide, are described in this section. 
Cyclophosphamide is an odorless slightly bitter white or almost white fine crystalline 
powder at room temperature. It is soluble in water (40 g/l), ethanol (~750 g/l), 
chloroform, dioxane, and glycols, and slightly soluble in benzene, carbon tetrachloride, 
ether, and acetone[14].  
With a predicted logP of 0,63, a molecular weight of 279,10 g/mol, 2 hydrogen bond 
donors and 5 hydrogen bond acceptors, cyclophosphamide complies with Lipinski’s 
rule of five (logP < 50, molecular weight < 500 g/mol, hydrogen bond donors ≤ 5, and 
hydrogen bond acceptors ≤ 10)[14].   
Cyclophosphamide is a weak acid, with an experimental pKa of 6.0[15]. Consequently, 
it is to be expected that the drug will absorb well from the gastrointestinal tract, 
although no data on the specific site of absorption is available. On the other hand, 
preclinical data suggest that weakly acidic drugs such as cyclophophosphamide 
enhance intratumor uptake, since the acidic extracellular pH in human tumors 
facilitates their diffusion through membranes[16]. 
Finally, it must be said that the melting range of the crystal form is low (49,5-53ºC)[14] 
and that the drug has low flowability and compressibility.   
4.1.3. Stability  
Cyclophosphamide is sensitive to oxidation, moisture, light[17], temperature, and 
pH[18]. It has also been reported that mechanical treatment of the monohydrate form 
can affect its stability[19].  
One the one hand, degradation of cyclophosphamide monohydrate in aqueous solution 
is due to hydrolysis (cyclophosphamide structure has several hydrolysable groups, like 
phosphorodiamide) loss of a chloride ion, or both. An increase in temperature, as well 
as the presence of benzyl alcohol, accelerates the rate of breakdown[18]. 
Decomposition of the drug in aromatic elixir (33% water, 33% sucrose, and 33% 
alcohol) is slower, what may reflect the decreased water concentration, while at 
extreme pHs it is susceptible to undergo specific acid and specific base catalysis[20].  
On the other hand, the monohydrate form of cyclophosphamide is converted to the 
anhydrous one through a metastable phase that gives rise to a sticky gel which 
decreases the rate of release and the bioavailability of the drug. These forms can be 
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detected at about 39ºC, and appear when the drug is desiccated, as well as with 
mechanical treatment. Indeed, cyclophosphamide monohydrate is only stable if the 
relative humidity is higher than 70% and the temperature lower than 30ºC[19].  
4.1.4. Pharmacokinetics 
Many studies regarding the pharmacokinetics of cyclophosphamide have been 
conducted. Nevertheless, the relations between pharmacokinetics and 
pharmacodynamics of cyclophosphamide are not fully established yet. This might be 
due to interindividual variations in the metabolism and distribution of the drug, since 
cyclophosphamide itself is inactive. Hence, the pharmacokinetics of its active 
metabolites should be the one to be considered for predicting drug efficacy[21]. 
Difficulty in understanding exposition to the active compounds is increased by the fact 
that cyclophosphamide induces its own metabolism after repeated administration. This 
decreases its elimination half-life and increases its total body clearance, thus reducing 
drug exposure, expressed as the area under the plasma concentration-time curve 
(AUC). However, it is controversial whether the subsequent increase in the rate of 
formation of the active metabolites correlates with an increase in their AUC[21].  
In addition, nonlinear elimination of high-dose cyclophosphamide, which is likely to 
cause saturability of 4-hydroxilation reducing the formation of 4-
hydroxycyclophosphamide, a metabolite involved in the biological activity, has been 
described[21].  
Finally, since cyclophosphamide is largely metabolized, drug-drug interactions that 
cause modifications in its activation, inactivation and detoxification processes have a 
major impact in its pharmacokinetics[21]. 
4.1.4.1. Absorption  
In order to reach systemic circulation, orally administered drugs need to be absorbed 
through the gastrointestinal wall. Absorption is only possible if drugs are in solution; 
thus, prior to crossing the physiological membranes solid forms like tablets must be 
able to disintegrate and deaggregate (during the process known as liberation). 
Consequently, water solubility is of vital importance[22].    
The other fundamental parameters controlling drug absorption are drug permeability, 
which is based on the drug n octanol/water partition coefficient P (a measure of drug 
hydrophobicity), and drug ionization[22]. 
Technological (e.g. particle size), and physiological characteristics (e.g. absorption 
membrane, gastric pH, bowel transit time) module the above parameters. However, 
only technological properties affecting the dissolution process can be modified by 
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physical procedures. Thus, the absorption rate of a specific drug can only be modified 
by controlling its dissolution process by means of pharmaceutical technology.  
 Finally, it must be said that, although a high absorption does not necessary imply a 
high bioavailability, a high oral bioavailability correlates with a high gastrointestinal 
absorption.  
The Biopharmaceutics Classification System (BCS) Guidance classifies drug 
substances in 4 different classes according to their solubility and permeability (Class I - 
High Permeability, High Solubility, Class II - High Permeability, Low Solubility, Class III 
- Low Permeability, High Solubility, Class IV - Low Permeability, Low Solubility)[23]. 
According to BCS, cyclophosphamide, with an aqueous solubility of 40 g/L, is highly 
soluble in water (highest dose strength soluble in < 250 ml water over a pH range of 1 
to 7.5), as well as highly permeable (extent of absorption in humans > 90% of an 
administered dose, based on mass-balance or in comparison to an intravenous 
reference dose), thus pertaining to class I[24]. Consequently, nor dissolution neither 
permeability of cyclophosphamide should be limitating factors for its gastrointestinal 
absorption. 
The latter classification is in line with in vivo studies regarding the pharmacokinetics of 
orally administered cyclophosphamide, which have demonstrated that the drug is well 
absorbed in humans, with peak concentration (Cmax) occurring after 1-3 hours (tmax) 
following oral administration and an oral bioavailability of 85-100%[21]. This small 
decrease in bioavailability in comparison with the intravenous formulation, which by 
definition is 100%, is due to the first pass effect in the liver and gut, where a fraction of 
drug is metabolized[25]. In addition, Navid et. al.[26], in their recent study of low-dose 
cyclophosphamide administered in children and young adults, reported an oral 
absorption rate constant (Ka) of 0,17 h
-1 (0,15-0,21 h-1). 
4.1.4.2. Disposition 
Disposition is a dynamic process where distribution, metabolism and excretion take 
place at the same time. Elimination half-life is the main parameter representing 
cyclophosphamide disposition, and ranges between 5 and 9 hours over a large 
concentration range. However, it appears to be shorter for children and young adults 
compared with adults as a result of increased CYP activity[21].   
Distribution 
After oral and intravenous administration, cyclophosphamide is rapidly distributed 
throughout the body with a low degree of plasma protein binding and a volume of 
distribution of 30-50L, which approximates to total body water[21]. In contrast, the 
ability of protein binding is higher for its metabolite, 4-hydroxycyclophosphamide 
(<67%)[25]. 
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Cyclophosphamide enters the cells, such as hepatocytes, via passive diffusion and 
active transport, where it is converted into 4-hydroycyclohposphamide. This compound 
diffuses into the plasma and, because it is relatively nonpolar, enters target cells via 
passive diffusion. Here it is trapped (weakly acid drugs such as cyclophosphamide are 
more likely to be in the ionized form inside the tumor cells due to its less acidic pH 
compared to the extracellular one) and converted into phosphoramide mustard. 
Although phospohramide mustard is also produced extracellularly, it is highly polar and 
thus cannot diffuse through the lipid bilayer of cells.  
Apart from entering hepatocytes, cyclophosphamide is extensively bound by 
erythrocytes, which may be a carrier of 4-hydroxycyclophosphamide to the tumor site. 
Cyclophosphamide may also enter into cerebrospinal fluid through the blood brain 
barrier. Penetration in the brain is limited for its metabolites, which undergo higher 
plasma protein binding and are more polar[25].  
Metabolism 
Approximately 70-80% of the 
administered dose of 
cyclophosphamide is activated in the 
liver by CYP450, such as CYP2A6, 
3A4, 3A5, 2C9, 2C18, 2C19, and 
especially 2B6, to form 4-
hydroxicyclophosphamide. This 
compound is in equilibrium with its 
ring-open tautomer aldophosphamide 
and spontaneously decomposes into 
phosphoramide mustard by β-
elimination of acrolein. 
Phosphoramide mustard is a 
bifunctional DNA alkylating agent 
considered to be the ultimate 
metabolite responsible for the 
alkylating effect of the drug, whereas 
acrolein is a highly reactive aldehyde 
and may enhance cyclophosphamide-
induced cell damage by depletion of 
cellular glutathione by conjugation[21].  
Cyclophosphamide may be directly detoxified by chain oxidation, leading to the 
formation of chloroacetaldehyde, while 4-hydroxycyclophosphamide and 
aldophosphamide are irreversibly deactivated by an oxidative reaction to 4-
ketocyclophosphamide and carboxyphosphamide, respectively. Detoxification of 4-
hydroxicyclophophamide, phosphoramide mustard and acrolein may also occur via 
intracellular conjugation with glutathione[21].  
Figure 4. Metabolism of cyclophosphamide.[21] 
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Finally, the appearance of the metabolite nor-nitrogen mustard in plasma and urine is 
the result of decomposition of cyclophosphamide and its metabolites, particularly 
phosphoramide mustard and carboxyphosphamide[21]. 
Excretion 
Between 30-60% of the total cyclophosphamide dose is eliminated renally as 
cyclophosphamide (less than 20% of the administered dose) or metabolites, while a 
very small fraction is eliminated via faeces and expired air. The major metabolite found 
in urine is carboxyphosphamide, although large interindividual variability in its urinary 
excretion has been seen. Urinary elimination of cyclophosphamide and its metabolites 
is almost complete 24 hours after the start of treatment[21]. 
Total systemic clearance of cyclophosphamide ranges from 4-5 L/h, of which the 
greater part is nonrenal clearance, probably due to extensive renal tubular 
reabsorption. However, it has been shown that renal clearance of cyclophosphamide is 
dependent on urine flow[21].    
4.2. The Sugar-coating Technique  
Tablets may be coated for a variety of reasons, including:  
– Masking unpleasant color, flavor or odor. 
– Enhancing administration by presenting a softer and slider surface. 
– Protecting the active ingredient from atmospheric agents such as air, moisture 
or light. 
– Avoiding incompatibilities by incorporating separately (coat and nucleus) non-
compatible active ingredients. 
– Modifying bioavailability (sugar-coating usually does not pursue this goal, in 
contrast to film-coating)[27]. 
– Protecting an acid labile drug from the gastric environment[28]. 
– Protecting the gastric mucosa from the action of the active ingredient. 
– Differentiating among pharmaceutical formulations during the manufacturing 
process. 
– Improving product appearance 
– Improving product robustness because coated products generally are more 
resistant to abrasion and attrition[29].  
There are several sugar-coating techniques, but the essential four major ones today 
are the following: Sugar-coating, film-coating, microencapsulation, and compression 
coating[29]. Recent trends in tablet coating techniques also include electrostatic dry 
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coating, magnetically assisted impaction coating (MAIC), vacuum film-coating, and dip 
coating[28]. In this section we will focus on tablet sugar-coating.      
4.2.1. Origins and Evolution of the Sugar-coating Technique  
Coating of medicinal products is one of the most ancient pharmaceutical processes. 
According to this, in the 1st and 2nd centuries AD the coating process was already 
common in Egypt to cover pills which tasted bad. One of the first written references of 
coated forms appeared in the Islamic literature by the hand of Rhaces (850-923)[30]. 
In the middle ages, the popularity of coated baked goods gave rise to the introduction 
of the first coated medicines to the market. In the 14Ith century, dragee manufacturing 
as it is known today started, but sugar-coatings were not fully developed until the mid-
19th century (two of the first patents of the sugar-coating technique date back to 1837 
and 1840)[30]. 
Until the forties, evolution of the sugar-coating process remained static[30], but soon 
the development of the film-coating technology and the advances that came with it, 
such as the design of new equipment, benefited the sugar-coating process, creating 
fully automated processes that can produce a batch in less than one day[29]. 
4.2.2. What Is Tablet Sugar-coating? 
Tablet is a pharmaceutical solid dosage form comprising a mixture of active 
substances and excipients pressed or compacted into a solid. Tablet is one of the most 
preferred dosage forms all over the world, and most drug molecules can be formulated 
in a tablet[31].  
Coating is a process by which an essentially dry, outer layer of coating material is 
applied to the surface of a dosage form to achieve specific benefits. Coating may be 
applied to a wide range of oral solid dosage forms, including tablets, capsules, 
particles, powders, pellets, and drug crystals[28].  
Tablet sugar-coating, also known as “dragée”, involves the application of a continuous 
and homogeneous sugar (sucrose) coat on the tablet (nucleus or core)[30]. Unlike film-
coating, sugar-coating is a multistep process which requires a fair degree of skill; 
although some approaches to shorten the traditional technique have recently been 
made[32]. 
The tablet sugar-coating process has many disadvantages in terms of process length 
(it takes up to several days), process difficulty (it is characterized by delicate 
operations), and need for highly skilled operators.  Another possible drawback is the 
increased bulk of the finished tablet. Despite these undoubted disadvantages, it can 
have certain advantages: Well tolerated and widely accepted non-expensive 
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excipients, simple equipment, controlled non-critical process which can meet modern 
GMP (Good Manufacturing Practices) standards, availability to work with softer and 
more friable nucleus than those required in the film-coating process, and obtainment of 
more stable tablets compared to the ones resulting from the film-coating process[32].  
4.2.3. The Sugar-coating Process 
4.2.3.1. Requirements of the Tablet Cores to Be Coated 
Tablets that are to be coated must possess the proper physical characteristics. 
Otherwise, the coating process might not succeed[33]. 
In the coating process, the tablets roll in a coating pan as the coating composition is 
applied. To tolerate the intense attrition of tablets striking other tablets or walls of the 
coating equipment, the tablets must be resistant to abrasion. So, mechanical 
resistance (hardness and friability) must be high[27].    
Ideally, the tablets used should have a biconvex shape with minimal edges[27], since 
the more convex the surface is the fewer difficulties will be encountered with tablets 
agglomeration[33]. In addition, the corners of biconvex tablets are easier to coat.    
The sugar-coating process involves high temperatures. Because of this, it is important 
to keep moisture at a low level[27]. Furthermore, tablets must be compatible with the 
coating materials and the tablet surface must be smooth so that the imperfections are 
covered. 
4.2.3.2. Equipment 
Historically, the sugar-coating process has been 
performed in conventional coating pans. These 
pans consist of an ellipsoid metal drum[27] of 
stainless steel with a unique opening angularly 
mounted on a stand[33]. Throughout the coating 
process, the core bed is moved in the container, 
which rotates on an inclined axis by motor at the 
same time that the coating liquid is fed through a 
spraying nozzle which is installed at the front of the 
opening. Cores get coated as they enter the spray 
zone prior to cascading down and merging into the 
bulk of the core bed[34]. Additionally, the coating 
pan is fitted with a means of supplying drying air to 
the tablets and an exhaust to remove moisture and 
dust-laden air from the pan[29].  
 
Figure 5. Traditional coating pan 
exposed in the Faculty of Pharmacy of 
the University of Barcelona. 
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Early sugar-coating pans used in the pharmaceutical industry came from those 
originally used for the production of candies[34]. Conversely to present conventional 
coating pans, the latter ones were made of copper instead of stainless steel[35]. On the 
other hand, they used to be attached to a blower vacuum to facilitate evaporation of 
moisture, and its container was rotated manually by means of a gear directed by a 
strap. The coating syrup was also applied manually on the core bed[36].  
In general, conventional pan coaters suffer from two disadvantages: Inefficient particle 
movement resulting in the appearance of so-called “dead zones” that impair 
homogeneous mixing of the core bed, and inadequate air transport causing insufficient 
drying of the core bed[34].  
To overcome these drawbacks, over the 20th century, with the raise of the film-coating 
technology, several new coating machines reached the market. Although some of them 
were specifically designed for film-coating, such as fluidizer beds, others have been 
widely used for sugar-coating as well[32]. This new equipment differs mainly from the 
standard coating pans described above in the position of the rotating axis, which is 
horizontal[34].    
In this regard, the introduction of pan coaters rotating on horizontal axis provided with 
baffles or blades which contributed to improvements in the particle movement and so to 
more uniform mixing is remarkable. The Pellegrini pan, which provides an enclosed 
coating system, was one of the first to incorporate such novelties[34]. 
On the other hand, with the aim to improve the drying efficiency of the conventional 
system, where only the surface of the core bed is exposed to the drying air, two 
different drying gadgets were developed: The immersion tube and the immersion 
sword, in which drying air is introduced through a perforated tube or metal sword, 
respectively, immersed in the tablet bed[34].  
Another approach to increasing the drying efficiency is the invention of perforated pans. 
According to this, a major advance in pan coating technology was the introduction of 
the side-vented pan concept[29]. This innovation was developed by Eli Lilly and 
formally designated as the Acela-cota[29], an enclosed coating pan in which drying air 
is directed in to drum, passes through bed, and is exhausted through perforations in to 
drum[33].  
Acela-cota was such a revolution that it has formed the basis for a wide range of 
partially or fully perforated pans known as side-vented pans[29], which are currently 
used almost exclusively for sugar-coating. Some typical examples of this modern pan 
coating equipment include: Hi-Coater, Premier Coater, HTF/150, IDA, and Glatt, which 
also provide means for automating the sugar-coating process[37].  
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4.2.3.3. Traditional Sugar-coating Process: Stages 
A typical sugar-coating process takes some days and encompasses five stages, with a 
final optional stage: Sealing, subcoating, smoothing, color coating, polishing, and 
printing (optional)[30]. Throughout these stages, tablet cores are successively treated 
with aqueous sucrose solutions which, depending on the stage of coating reached, 
may contain other functional ingredients. Typically, in each stage heated air is blown 
across the drum to warm the cores up. Then, a single liquid application which will 
spread over the entire tablet bed is made. At this point, drying air is used to dry the 
application. The whole cycle is then successively repeated until the desired coating is 
obtained[32]. The overall process takes place in a coating pan, and usually results in a 
final product weight gain of 30-100% of the weight of the original tablet core[27].  
Sealing 
The purpose of sealing is to protect the cores from the water of the successive layers 
and from the abrasion they suffer throughout the process[27], as well as to prevent 
some tablet core ingredients from migrating into the coating[35].  
To accomplish this, the cores are exposed to water insoluble film-forming polymers 
dissolved in organic solvents (ethanol, acetone, ethyl acetate), which enable the 
formation of a waterproof insulating film[27]. Examples of polymers that might be used 
include shellac[27][32], cellulose acetate phthalate (CAP)[27][35][32], hydroxypropyl 
methylcellulose (HPMC)[35], polyvinyl acetate phthalate (PVAP)[35][32], 
zein[35][32], high-molecular weight polyethylene glycol[27], and polymethacrylates[27]. 
These solutions also include small amounts of plasticizers such as castor oil and alkyl 
phthalates to provide film elasticity and ensure waterproofing[35]. The use of dusting 
powders such as talc to prevent the tablets from sticking together or to the pan has 
also been described[35][32]. 
During the sealing stage, the general process of blowing air, applying the sealing 
solution and drying is repeated until reaching a weight increase of 1-3 %[27].  
 
Figure 5. Pellegrini pan[47] Figure 6. Acela Cota
®
[48] 
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Subcoating 
Subcoating is the first major step of the sugar-coating process, which provides the 
means for rounding off the tablet edges[27][35] and for reaching the definitive tablet 
shape[27] while building up the core weight[35] (in this stage the weight increase is 
around 30%-50%[32]). To get effective coverage of the cores and avoid twinning, tablet 
shape is especially important in this stage[27]. According to this, biconvex tablets are 
preferable, as discussed in section 4.2.3.1. 
Effective subcoating is achieved through a lamination process[35], which consists of 
the application of a concentrated gummy syrup (binder solution) containing sucrose 
and small amounts (3-5%) of binders such as gelatin, polyvinylpyrrolidone, acacia gum, 
etc., followed by addition of powders (fillers and detackifiers)[27]. Since in the 
lamination process overdusting can create tablets with brittle coatings, a suspension 
subcoating process in which a suspension of the gummy syrup and the powder is 
applied over the tablets is frequently used. In addition, the latter approach increases 
the quality of the coated-tablets, facilitates automation and reduces the complexity of 
the process in comparison with the first one[35]. 
Smoothing (Grossing) 
The purpose of the smoothing or grossing stage is to achieve a smooth surface at the 
same time that the nucleuses reach the desired size (approximately 40% of the initial 
weight)[30]. This is possible by successive applications of a diluted sucrose syrup (70% 
w/w[35][29]), depending on the degree of smoothness acquired in the subcoating 
stage[35]. In some cases, the smoothing coating can also contain titanium dioxide, an 
opacifier/whitening agent, or other colorants. In addition, large degrees of unevenness 
might require some subcoating solids in low concentrations in the initial smoothing 
coats, such as talc, calcium carbonate or corn starch[35]. 
Color Coating 
Color coating is one of the most important steps in the sugar-coating process as it has 
immediate visual impact[35][32], but it is often the most critical one[29]. Color coating 
can be tackled by the use of appropriate coloring agents dissolved or dispersed in a 
simple syrup[35]. Depending on whether these agents are water-soluble or water 
insoluble, two different color coating techniques exist. The most ancient one relies on 
the application of water soluble dyes, whereas the second one uses modern 
predispersed suspensions of water-insoluble pigments, including inorganic pigments 
such as the opacifier titanium dioxide or iron oxides[35][32].  
SOLUBLE DYES WATER INSOLUBLE PIGMENTS 
The final color is determined by the overall 
thickness of the successive color layers, so 
irregularities in the surface of these layers 
result in an uneven color  
The final color is not dependent on the 
thickness of the color layer thanks to the use 
of opacifiers 
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Coating syrups are applied in increasing 
specific concentrations until reaching the 
target color, what can involve 30-50 color 
applications 
Coating syrups are applied in a single 
relatively high concentration of color 
The color layer is easily disrupted due to 
migration of the color to the tablet surface in 
case of underdrying or quick drying 
Color migration problems are not usual 
thanks to the water insoluble nature of the 
pigments 
Color uniformity is not maintained from batch 
to batch if the number of applications in each 
batch varies, since it depends on the 
thickness of the color layer 
Color uniformity is maintained from batch to 
batch even if the number of applications in 
each batch differs slightly, since the final 
color is not dependent on the thickness of the 
color layer 
The process is time-consuming and requires 
highly skilled operators 
The process is shorter thanks to the fact that 
the coating syrups are applied in a single 
concentration and that quick drying is 
possible 
Table 2. Differences between soluble dyes and water insoluble pigments[35][32]. 
Overall, although advantages of the pigment coating process tend to prevail, making it 
the process of choice, it must be said that coatings derived from pigments are generally 
not as bright as those obtained with soluble colorants[35].  
Polishing (Glossing) 
After the color-coating process the tablets have a matt appearance which requires a 
separate polishing step to give them the adequate degree of gloss. Polishing methods 
vary considerably, but it is generally important that the tablets are dry prior to 
polishing[35]. Some examples of polishing methods include: 
– Application of an organic solvent solution/suspension of waxes, for example 
carnauba and beeswax[35]. An available variant of this technique provides an 
emulsion of waxes in an aqueous continuous phase stabilized by a surfactant, 
with the advantage of aqueous processing[32]. 
– Finely powdered wax application[35]. 
– Mineral oil application[32]. 
– Pharmaceutical glazes containing shellac in alcohol with or without waxes[35]. 
The equipment available for carrying out the polishing stage includes polishing pans 
such as wax-lined pans and canvas-lined pans, although the procedure can also be 
performed in the sugar-coating pans where the prior steps take place, especially in 
automated approaches[35].    
Printing 
The aim of the printing process is to enable the product to be easily identified[30]. This 
might be done by engraving a product name, dosage strength or company name or 
logo on the tablet coating[35]. Indeed, some regulatory authorities demand or 
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encourage that tablets should possess some detailed identifying mark as part of the 
overall GMP requirements[32].    
Typically, such printing involves the application of a pharmaceutical ink to the coated 
tablet surface by means of a process known as offset rotogravure[35]. A typical edible 
pharmaceutical ink formulation suitable for this process consists of: Shellac, alcohol, 
pigment, lecithin, antifoam and other organic solvents. Shellac is the lacquer most 
commonly utilized, but is slowly giving ground to cellulose derivatives as it can pose 
severe stability problems. Lecithin is frequently included to maximize the quantity of 
pigment that can be utilized, while antifoam is necessary to prevent the foam build 
up[32].  
Recently, other technologies which are less sensitive to minor changes in procedure 
than the offset gravure process, such as the ink-jet printing technique, are being 
introduced[32].   
4.2.3.4. Automated and Fast Coating Systems 
Over the course of time, the pharmaceutical industry has witnessed a general transition 
away from manually operated sugar-coating processes to film-coating processes, 
where operator intervention is infrequent. Nevertheless, the sugar-coating process is 
still used by many companies that have invested in its complete modernization, which 
has allowed reduction of processing time (traditionally, the process could take up to 5 
days, whereas nowadays the time has been reduced to less than one day) and has 
lowered the numbered of operators needed in traditional sugar-coating. This has been 
possible through thin sugar-coating procedures (such as the uniform or fast sugar-
coating process known as Tucker) and process automation (in which coating 
application is accomplished using automated dosing techniques)[29]. 
Uniform or Fast Sugar-coating (Tucker) 
In the Tucker sugar-coating method, the subcoating and grossing stages are carried 
out simultaneously. This gives rise to a thinner cover than that resulting from the 
classical sugar-coating technique. The quality of the tablets obtained is also 
compromised compared to the ones of the traditional sugar-coating method. However, 
positive aspects of this technique are speed and possibility of automation[30].  
Automated Sugar-coating  
Dependence of operators in the sugar-coating process can be minimized through 
automation. However, the natural sequencing of events that are the basis of the sugar-
coating process adds a level of complexity when considering the implementation of 
automation. Recent initiatives such as Quality by Design (QbD), which aims to control 
all aspects of the process involved in the release of pharmaceuticals by designing fully 
optimized processes, creating an effective design space, and implementing in Process 
Analytical Technologies (PAT), simplify the challenges of automation[29]. Thus, 
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automation involves a series of regulating devices for temperature, airflow, spray rate 
and pan speed which enable to maintain a feedback control of the process[33]. An 
example of this is effective use of nIR (near infra-red) techniques such as the nIR 
sensor[29]. 
4.2.4. Quality Problems with Sugar-coated Tablets 
Finished sugar-coated tablets can present several quality problems, such as chipping 
of coatings, cracking of the coating, inability to dry sugar-coatings properly, twinning, 
uneven color, blooming and sweating, and marbling[35].   
Chipping can be avoided with the inclusion of small quantities of polymers, whereas it 
is exacerbated with excessive use of fillers and pigments which increase the brittleness 
of the sugar-coating. Cracking might be due to moisture absorption by the tablet core, 
and can be minimized by appropriate use of a seal coat. Inability to dry sugar-coatings 
properly is often an indicator that excessive levels of invert sugar are present. This 
might happen when sucrose syrups are exposed to elevated temperatures under acidic 
conditions for extended periods of time. Twinning usually occurs because of the sticky 
nature of sugar-coating formulations, and becomes a problem when the tablets being 
coated have flat surfaces. Uneven color can be caused by many factors, such as color 
migration of water-soluble dyes, excessive drying between color applications, etc. 
Blooming and sweating occur when residual moisture of the finished sugar-coated 
tablets diffuses out, causing appearance alterations in the tablet surface and sticking of 
the tablets. Finally, failure to achieve the requisite smoothness often results in a 
marbled appearance on polishing[35].   
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5. RESULTS AND DISCUSSION 
5.1. Justification of the Route of Administration  
Is Oral Administration of Cyclophosphamide Pharmacokinetically Equivalent to 
Intravenous Administration? 
As reviewed in the pharmacokinetics section, cyclophosphamide has a high oral 
bioavailability. Thus, it is reasonable to assume that oral administration of the drug 
might be a great alternative to intravenous administration. However, the fact that 
cyclophosphamide itself is not responsible for the final biological activity should not be 
overlooked. For instance, the pharmacokinetics of cyclophosphamide metabolites 
which contribute to the cytotoxic activity must also be studied.  
Struck et al.[38], in the first study to compare plasma levels of the two main cytotoxic 
metabolites of cyclophosphamide (phosphoramide mustard and 4-
hydroxycyclophosphamide), reported that exposure to these compounds, measured as 
the mean AUC values of the participants in the study, was similar after administration 
of an oral liquid formulation and an intravenous preparation of the same 
cyclophosphamide dose. Conversely, exposure to cyclophosphamide was higher when 
administered intravenously due to the first past effect of the oral preparation, which 
decreases the bioavailability of the parental compound without compromising clinical 
efficacy (see figure 7).  
 
 
 
 
 
 
 
Figure 7. Comparison of mean AUC values for cyclophosphamide, 4-
hidroxycyclophosphamide, and phosphoramide mustard after oral and intravenous 
administration.[38] 
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These data support that the intravenous and oral routes are interchangeably in the 
clinical practice in terms of pharmacokinetic/pharmacodynamic relationships and 
explain the current availability of both intravenous and oral forms.  
5.2. Justification of the Dosage Form 
5.2.1. Pharmacokinetic Justification 
Are Cyclophosphamide Sugar-coated Tablets Pharmacokinetically Equivalent to 
Capsules and Oral Liquid Forms? 
Few studies regarding oral bioavailability of cyclophosphamide have been conducted. 
In some of these studies patients were administered cyclophosphamide tablets, while 
in others oral liquid formulations prepared using cyclophosphamide powder for injection 
were preferred. No study regarding the pharmacokinetics of cyclophosphamide 
capsules, recently introduced in the United States, has been found. However, this new 
dosage form has demonstrated bioequivalence with the tablet formulation[39].   
The mean AUC values for cyclophosphamide after oral administration obtained in 
some of the studies regarding the pharmacokinetics of orally administered 
cyclophosphamide are summarized in table 3. 
NO. OF 
PATIENTS 
DOSE REGIMEN FORMULATION AUC
0- (mol/L*h) REFERENCE 
18
a,b
 
50 mg/m
2
 once daily 
for 21 days 
Liquid 
formulation/tablet 
62,5 (49.2–80.9) [26] 
7 600 – 1000 mg/m
2
  Elixir syrup 590,50  184,42 [38] 
12
c,d
 
175 mg/m
2
 once daily 
on 4 consecutive days 
Endoxan
®
, gastric 
juice resistant 
dragees 
141,5  53,6 [40] 
12
c,d
 
175 mg/m
2
 once daily 
on 4 consecutive days 
ASTA 82134 I, 
gastric juice 
soluble dragees 
138,7  34,7 [40] 
Table 3. Mean AUCs for cyclophosphamide after oral administration in different studies. 
a
Pediatric patients; 
b
Patients also receiving bevazizumab and sorafenib; 
c
Female patients; 
d
Patients 
undergoing Cyclophosphamide Methotrexate Fluorouracil (CMF) therapy.  
Data are presented as mean  SD or median and the range. 
In a recent study in which low-dose cyclophosphamide was administered in children 
and young adults with refractory/recurrent solid tumors in combination with 
bevazizumab and sorafenib, Navid et. al.[26] reported that the AUC difference of 4-
hydroxycyclophosphamide administered as an oral liquid formulation or in tablet form  
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was not statistically significant, suggesting that oral liquid formulations, despite not 
being marketed as such, might be an alternative when managing pediatric patients.  
On the other hand, Brujin et al.[41], when studying the pharmacokinetics of intravenous 
and oral cyclophosphamide in the presence of methotrexate ant fluorouracil, found that 
lag-times and mean absorption times of the drug given in tablets were prolonged in 
comparison with those resulting from administration of oral liquid preparations, 
although extent bioavailability of the drug administered by tablets was enough.  
Years ago, cyclophosphamide coated tablets were available as gastric juice resistant 
or enteric tablets and as soluble or immediate release tablets, as shown in table 4 with 
Endoxan® (gastric juice resistant dragee) and ASTA (juice soluble dragee). Significant 
differences in the rate of oral bioavailability (tmax) between these two types of 
formulations were reported by Wagner et. al.[40] when studying the bioavailability of 
cyclophosphamide from three oral formulations. In this study, the time for the enteric 
formulation Endoxan® to reach the maximum concentration (tmax) was higher (2,5  
1,81 h) than that needed for the immediate release tablets (1,13  0,83 and 1,82  
0,59). Nowadays, in most countries around the world cyclophosphamide tablets are 
commercialized by Baxter Oncology and are no longer enteric tablets but immediate 
release ones.   
In conclusion, available pharmacokinetic data indicate that cyclophosphamide can be 
administered orally in different pharmaceutical forms, such as tablets, capsules and 
liquid preparations, with minimal changes in the pharmacokinetic profile. In some 
cases, rate bioavailability might be decreased for tablets, especially if these are gastric 
juice resistant. However, as said before, when considering if two or more 
pharmaceutical forms or routes of administration are interchangeable, the AUCs of the 
active metabolites, rather than the ones of the prodrug, should be taken into 
consideration.     
5.2.2. Stability Justification 
Are Cyclophosphamide Coated Tablets Better Than Capsules and Oral Liquid Forms 
from a Stability Point of View?  
As stated before, oral commercially available dosage forms of cyclophosphamide 
include coated tablets (in Spain) and capsules (in the United States). Although in young 
children it is preferable to administer the drug as an oral liquid formulation, and so is 
frequently done in the clinical practice, this preparation is not marketed. The 
explanation for this finding is likely to lie in the compromised stability of 
cyclophosphamide in aqueous vehicles and aromatic elixirs, as introduced in 4.1.3. 
In 1973, Brook D. et al[42] showed that extemporaneous oral suspensions of 
cyclophosphamide powder for injection in aromatic elixir were stable for 2 weeks at 
5ºC. A recent study of R. Kennedy et al[43] has proven that cyclophosphamide is 
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stable at 4ºC in both simple syrup (85 g sucrose/100 ml water) and Ora-Plus (97% 
Water, <1% sodium phosphate monobasic, <1% sodium carboxymethylcellulose, <1%  
microcrystalline cellulose, <1% xanthan gum, <1% carrageenan) for approximately two 
months (56 days) in a concentration of 10 mg/ml. In fact, the formulations proposed in 
both studies are likely to be stable for longer if the mentioned storage conditions are 
maintained, but later time points have not been investigated. On the contrary, the shelf 
lives of cyclophosphamide in simple syrup and in Ora-Plus at room temperature are 8 
and 3 days, respectively. These data explain the reason why oral liquid commercial 
preparations of cyclophosphamide are not available, since they would have a very 
short shelf-life and would require special conservation conditions.  
Unlike liquid oral preparations, commercialized cyclophosphamide coated tablets have 
an expiring period of 36 months if stored below 25ºC[44], which enables distribution of 
the medication, safekeeping in the pharmacy and storage in the patients’ home. In the 
same line, Roxane’s cyclophosphamide capsules also have an acceptable shelf-life (24 
months if stored at 20 to 25ºC[39]). However, the shelf-life difference of one year 
between the two solid forms helps conclude that, from a stability point of view, 
cyclophosphamide coated tablets is the most convenient dosage form among those 
used in the clinical practice. 
Why Are Cyclophosphamide Tablets Coated? 
Cyclophosphamide is sensitive to oxidation, moisture, light[17], temperature, pH[18], 
and mechanical treatment[19], as reviewed in 4.1.3. Hence, it could be assumed that 
the compromised chemical and physical stability of the active ingredient is one of the 
main reasons for tablet coating, since in this way it can be protected from the 
atmospheric agents that are likely to accelerate its degradation. However, avoidance of 
direct contact with the active ingredient is another major reason for tablet coating due 
to it carcinogenicity. 
5.3. Cyclophosphamide Sugar-coated Tablets: Review of 
the Pharmaceutical Formulation and Shortcomings     
The aim of this section has been to classify the different excipients of 
cyclophosphamide sugar-coated tablets according to the role they probably play in the 
pharmaceutical formulation. Hence, the excipients which appear in the summary of 
product characteristics of Baxter cyclophosphamide formulation have been used. By 
doing this, the manufacturing method undergone by the drug product has been 
deduced. Finally, attention has been drawn to the shortcomings of Baxter’s 
cyclophosphamide sugar-coated tablets.      
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5.3.1. Review of the Pharmaceutical Formulation 
Baxter Oncology cyclophosphamide sugar-coated tablets are white rounded tablets 
with blue flecks containing 25 or 50 mg of cyclophosphamide monohydrate equivalent 
to 25 or 50 mg of the anhydrous form[2].   
TABLET CORE EXCIPIENTS 
Excipient[2][44] Function Description[45] 
 
Maize starch 
 
Disintegrant 
 
Matt, white to slightly yellowish, tasteless, 
very fine powder derived from the corn 
(maize) grain. It is practically insoluble in 
cold ethanol and in cold water, it swells 
instantaneously in water by about 5–10% at 
37°C, and becomes soluble in hot water at 
temperatures above the gelatinization 
temperature. 
Lactose monohydrate Diluent 
White to off-white, odorless, slightly sweet-
tasting, crystalline powder soluble in water 
and practically insoluble in ethanol, ether 
and chloroform.  
Calcium hydrogen 
phosphate dehydrate 
Binder/Diluent 
White, odorless, tasteless powder or 
crystalline solid characterized by being 
nonhygroscopic and practically insoluble in 
ethanol, ether, and water, but soluble in 
dilute acids. 
Talc Antiadherent 
Purified, hydrated, magnesium silicate 
which may contain small, variable amounts 
of aluminum silicate and iron. Talc occurs 
as a very fine, white to grayish-white, 
odorless, unctuous, crystalline powder 
which adheres readily to the skin and is soft 
to the touch and free from grittiness. It is 
practically insoluble in water and organic 
solvents.  
Magnesium stearate 
 
 
 
Lubricant 
 
 
 
Magnesium stearate is a very fine, light 
white, precipitated or milled, impalpable 
powder of low bulk density, having a faint 
odor of stearic acid and a characteristic 
taste. The powder is greasy to the touch 
and readily adheres to the skin. It is 
practically insoluble in ethanol, ether and 
water; and slightly soluble in warm ethanol. 
Gelatin Binder 
Gelatin is a mixture of purified protein 
fractions which occurs as a light-amber to 
faintly yellow-colored, vitreous, brittle solid. 
It is practically odorless and tasteless. In 
water, it swells and softens, gradually 
absorbing between five and 10 times its 
own weight of water.  Above 40°C it is 
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soluble in water, forming a colloidal 
solution, which gels on cooling to 35–40°C. 
Glycerol Humectant 
Clear, colorless, odorless, viscous, 
hygroscopic liquid, which has a sweet taste 
and is soluble in water and ethanol and 
practically insoluble in organic solvents and 
oils.  
Table 4. Tablet core excipients of Baxter Cyclophosphamide coated tablets, probable functionality in the 
pharmaceutical formulation and description. 
COATING EXCIPIENTS 
Excipient[2][44] Function  Description[45] 
Sucrose  Coating agent 
Sweet, odorless crystalline sugar obtained 
from sugar cane, sugar beet, and other 
sources. It is hygroscopic, soluble in 
water, and slightly soluble in ethanol.  
Titanium dioxide Opacifier 
White, amorphous, odorless, and 
tasteless nonhygroscopic powder which is 
practically insoluble in water and organic 
solvents.  
Calcium carbonate Bulking agent  
Odorless tasteless white powder or 
crystals practically insoluble in ethanol 
and water. 
Talc Antiadherent 
Purified, hydrated, magnesium silicate 
which may contain small, variable 
amounts of aluminum silicate and iron. 
Talc occurs as a very fine, white to 
grayish-white, odorless, unctuous, 
crystalline powder which adheres readily 
to the skin and is soft to the touch and 
free from grittiness. It is practically 
insoluble in water and organic solvents. 
Macrogol 35000  Plasticizer/Binder 
Free-flowing high molecular weight 
(HMW) polyethylene glycol powder with a 
faint, sweet odor which is soluble in water, 
ethanol, acetone, and insoluble in fats and 
mineral oil.  
Silica colloidal 
anhydrous  
Glidant 
Light, fine, white or almost white 
amorphous powder, not wettable by 
water, which is practically insoluble in 
water and insoluble in organic solvents. 
Povidone Binder 
Synthetic polymer consisting essentially of 
linear 1-vinyl-2-pyrrolidinone groups, 
characterized by its viscosity in aqueous 
solution. It occurs as a fine, white to 
creamy-white colored, odorless or almost 
odorless, hygroscopic powder. It is 
soluble in water, ethanol, ketone, and 
chloroform, and insoluble in ether and 
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mineral oils.  
Sodium 
carboxymethylcellulose 
Film-forming agent 
White to almost white, odorless, tasteless, 
granular powder. It is hygroscopic at high 
temperatures and humidities, and its 
solubility in water depends on the degree 
of substitution, while it is practically 
insoluble in ethanol, acetone, and ether.  
Polysorbate 20 Stabilizer/Plasticizer 
Yellow oily liquid containing a mixture of 
molecules of varying sizes resulting from 
the copolymerization of fatty acid esters of 
sorbitol and its anhydrides with 
oxyethylene. It is soluble in water and 
ethanol and insoluble in oil.  
Montan glycol wax Polishing agent 
Natural wax obtained from lignites, which 
contains pure wax (50-80%), resin (20-
40%) and bitumen (10-20%) and can be 
dissolved in many kinds of organic 
solvents. It occurs as a brown-black, 
tasteless solid, with good gloss and 
chemical stability and high melting point. 
FD&C Blue No. 1 
(Brilliant blue FCF) 
Coloring agent 
Aromatic disodium benzenesulfonate 
structure which occurs as blue powder or 
granules. It is soluble in water and slightly 
soluble in ethanol.  
D&C Yellow No. 10 
Aluminum lake 
(Quinoline yellow WS) 
Coloring agent 
Aluminum lake of yellow powders or 
granules of sulfonates of quinolones. It is 
insoluble in water. 
Table 5. Coating excipients of Baxter Cyclophosphamide coated tablets, probable functionality in the 
pharmaceutical formulation and description. 
From the use of glycerol in the tablet core formulation, it can be deduced that the 
tablets are obtained through an aqueous wet granulation process. This method of 
tablet manufacturing consists of a first granulation step in which the active ingredient, 
diluents, binders, disgregants, and other excipients, are mixed and formulated into 
granules by means of water as vehicle. This is followed by the compression of the 
granules with the help of lubricants, glidants, and antiadherents[29].  
Glycerol is a viscous, hygroscopic, water soluble liquid. Gelatin is a solid which is 
soluble in water only at relatively high temperatures (above 40ºC) and gels on cooling, 
whereas calcium hydrogen phosphate dehydrate is non-hygroscopic and has a low 
water solubility[45]. Consequently, glycerol might enhance the solubilization of gelatin 
and calcium hydrogen phosphate dehydrate in water by acting as a humectant, thus 
allowing these ingredients to form a binder solution that will be applied over the other 
excipients in the formulation. In conclusion, the use of a humectant brings in the need 
for an aqueous wet granulation process. 
 
 
Cyclophosphamide Sugar-coated Tablets – Final Degree Project 
 
35 
 
 
 
 
 
 
In relation to the coating process, sucrose and all the other excipients in the coating 
formulation indicate that the tablet nucleuses are covered by means of the sugar-
coating technique, described in 4.2.3.  
5.3.2. Shortcomings     
As already mentioned in previous sections, cyclophosphamide physical and chemical 
properties can be easily compromised when the drug is exposed to certain agents and 
conditions. This should be taken into account not only during the distribution and 
storage of the drug product, but also, and very importantly, during its manufacture. 
Thus, the excipients used in the formulation of the tablets should be carefully chosen, 
as well as the manufacturing process itself. 
Although Baxter’s formulation of cyclophosphamide sugar coated tablets provides good 
results (perfect white blue sugar-coated tablets with blue flecks are obtained), some of 
the excipients used might not be the most adequate in terms of drug stability. This is 
mainly due to the fact that they are subjected to certain manufacturing processes which 
require water as the principal vehicle and drying or heating steps, overlooking that 
cyclophosphamide is chemically labile in aqueous solution and that it is sensitive to 
humidity changes and high temperatures.  
This is the case of gelatin, a binder that yields strong granules and tablets of 
intermediate hardness, providing the tablet cores with the mechanical resistance 
needed to overcome the subsequent coating process[46]. However, in Baxter’s 
formulation, gelatin must be dissolved in water at high temperatures (above 40ºC) with 
the help of glycerol and cooled in order that gelation can occur. This requires a wet 
granulation process in which water is essential, exposing cyclophosphamide labile 
structure to hydrolysis. In addition, gelatin needs to be heated in order to solubilize, 
while wet granulation encompasses a drying stage. These latter processes could be 
detrimental for a thermolabile drug like cyclophosphamide, which undergoes gelation 
when heated and has a low melting range (49,5-53ºC), as introduced in sections 4.1.2. 
and 4.1.3.  
The use of sucrose as a coating agent by means of the sugar-coating technique is also 
subjected to utilizing water as coating vehicle, what, again, can result in the hydrolysis 
of cyclophosphamide. In addition, sugar-coating requires several cycles of drying that, 
Other 
excipients 
Binder solution + 
Certain excipients 
+ 
Mixing 
Granulation Drying Screening 
Granules 
Lubricants 
Lubrication 
Compression 
Tablets 
Figure 8: Overview of the stages in the manufacture of tablets by the wet granulation process. 
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if not carried out at cool temperature, might accelerate the degradation of 
cyclophosphamide monohydrate. Finally, sugar is likely to react with many functional 
groups, undergoes inversion and hydrolization at high temperatures and with the 
presence of acids, and may attack aluminum closures[45]. 
5.4. A New Approach to Cyclophosphamide Coated 
Tablets: Design of Cyclophosphamide Sorbitol Film-
coated Tablets 
Given that currently commercialized cyclophosphamide coated tablets undergo a 
complex and tedious manufacturing process that might compromise the stability of the 
active ingredient, it seems reasonable to assume that the need exists for a simple 
preparation of an oral solid dosage form comprising cyclophosphamide that diminishes 
the exposure of the active ingredient to stability compromising processes. In this 
section, a sorbitol film-coating formulation that could cover this necessity is disclosed. 
5.4.1. Formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INGREDIENT TABLET CORE/ 
COATING % 
QUANTITY (mg) 
 Tablet core 
API 
Cyclophosphamide 
monohydrate 
22 
53,45 (50 mg 
anhydrous) 
DC vehicle 
(Diluent/Binder) 
Microcrystalline 
cellulose (Vivapur
®
) 
43 102,00 
DC vehicle 
(Diluent/Binder) 
Anhydrous dibasic 
calcium phosphate 
(Anhydrous 
Encompress
®
) 
31 75,00 
Disintegrant 
Sodium starch glycolate 
(Explotab
®
) 
2,5 6,00 
Glidant 
Colloidal anhydrous 
silica (Aerosil
®
) 
0,5 1,15 
Lubricant Magnesium stearate 1 2,40 
 Coating 
Plasticizer Sorbitol 17 5,60 
Solvent/Plasticizer Glycerol 68 22,42 
Film-forming agent Povidone (Kollidon
®
) 5,2 1,72 
Coloring agent 
FD&C Blue No. 1 
(E133) Aluminum lake  
0,09 0,03 
Opacifier Titanium dioxide 0,7 0,23 
Solvent Water 9 3,00 
Figure 9. Formulation of cyclophosphamide sorbitol film-coated tablets. 
240 mg 
 
 
30 mg 
 
 
 
270 mg 
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The formulation proposed consists of sorbitol film-coated tablets comprising a tablet 
core obtained by direct compression and a sorbitol/glycerol coating achieved with the 
use of the film-coating technique. The tablet core weighs 240 mg and accounts for the 
major part of the dosage form, whereas the coating increases the bulk by an 11%, 
bringing in 30 additional mg. Accordingly, the final tablet weight is 270 mg.   
Like commercially available cyclophosphamide coated tablets, this formulation contains 
the required dose of cyclophosphamide monohydrate equivalent to 50 mg of anhydrous 
cyclophosphamide. The necessary quantity of cyclophosphamide monohydrate has 
been calculated as follows:  
0,05 g CPA ×
1 mol CPA
261,086 g CPA
×
1 mol CPA·H2O
1 mol CPA
×
279,10 g CPA H2O
1 mol CPA H2O
×
1000 mg
1 g
 = 53,45 mg CPA·H2O 
Hence, the tablet core contains 53,45 mg of cyclophosphamide monohydrate in 
conjunction with several excipients. These are microcrystalline cellulose and anhydrous 
dibasic calcium phosphate, as direct compression vehicles, colloidal anhydrous silica 
and magnesium stearate, as glidant and lubricant, respectively, and sodium starch 
glycolate, as super disintegrant.  
Microcrystalline cellulose is widely recognized to be one of the most common vehicles 
for direct compression, since it is not only free-flowing but also sufficiently cohesive to 
act as a binder[29]. Anhydrous dibasic calcium phosphate has been chosen because, 
when unmilled, has good compactation and flow properties which are ideal for direct 
compression[45]. In addition, the low hygroscopicity[45] of anhydrous dibasic calcium 
phosphate allows controlling the moisture of the preparation. Sodium starch glycolate 
at a low concentration is included in order to facilitate the liberation of the active 
ingredient. 
Microcrystalline cellulose and anhydrous dibasic calcium phosphate make up an 
important part of the tablet core. Incorporation of these excipients in elevated quantities 
is essential for assuring an adequate compression and achieving proper tablet cores, 
since cyclophosphamide itself does not possess the cohesive strength and flowability 
required to undergo direct compression on its own.    
On the other hand, the coating accounts for approximately 11% of the overall 
formulation, and is made up of povidone (film-forming agent), sorbitol (plasticizer) and 
glycerol (solvent/plasticizer) as the principal ingredients. Sorbitol and povidone are 
soluble in glycerol[45], which is used as the main coating solvent, allowing a significant 
reduction in the use of water. Nevertheless, given that it has a high boiling point[45], 
sorbitol is not expected to be fully eliminated in the drying stage. Consequently, a 
certain concentration of this ingredient will remain in the final tablets, thus enhancing 
the plasticizing action of sorbitol.  
A water insoluble colorant and an opacifier (FD&C Blue No. 1 aluminum lake and 
titanium dioxide, respectively) are also added in the coating suspension. FD&C Blue 
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No. 1 aluminum lake is encountered in a very low concentration in order to provide the 
tablets with the characteristic light blue shade of the traditional cyclophosphamide 
sugar-coated tablets, while titanium dioxide increases the film coverage and helps 
achieve the desired final color.  
The presented coated tablets are conceived to be produced by a simple, non-laborious 
manufacturing process. Hence, since direct compression requires fewer unit 
operations, only the blending of the tablet core excipients and the active ingredient will 
be necessary prior to compactation. Blending should be carried out in a mixer (e.g. a 
double-cone mixer) whereas compression must be executed by means of a tablet 
machine (e.g. a rotatory tablet machine). Since the active ingredient is heat sensitive, it 
might be recommendable to use Teflon® coated punches during compression, as they 
are resistant to heat. 
Once the tablet cores have been obtained, the coating suspension is ready to be 
sprayed over the tablet bed. An Acela Cota® pan, in which the spraying nozzle is 
positioned within a drum consisting of perforated walls and the drying air flows through 
an air supplying inlet into the pan and fluidizes the core bed[34], could be suitable for 
carrying out the film-coating process. 
5.4.2. Advantages 
The presented pharmaceutical formulation has certain advantages in comparison with 
the commercially available product.  The most relevant one is the reduction in the use 
of water, which is important in order to minimize the degradation of cyclophosphamide 
that is likely to take place when the drug is exposed to an aqueous medium.  
As already seen in section 5.3.1., Baxter’s cyclophosphamide sugar-coated tablets 
undergo an aqueous wet granulation process and are coated by means of the 
traditional sugar-coating method. Wet granulation requires the use of water in order to 
obtain the granules that will then be compressed, while in sugar-coating, sucrose is 
diluted in water to form the simple syrup that will be repeatedly applied over the tablet 
bed. In contrast, thanks to the variation of the excipients in the formulation, the 
presented cyclophosphamide coated-tablets can be obtained by direct compression 
followed by coverage through the film-coating technique.  
This significantly reduces the amount of water needed in the traditional process, since 
direct compression is water-free, while film-coating offers the possibility to use other 
solvents rather than water. Indeed, in the novel cyclophosphamide sorbitol film-coated 
tablets, water is reduced to approximately 9% of the overall coating suspension thanks 
to the use of glycerol as the main solvent. In addition, the fact that one application of 
the coating suspension is enough to achieve the desired coverage also minimizes 
exposure of the active ingredient to water. 
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Beyond enabling the avoidance of water, the use of direct compression eliminates the 
drying step required in wet granulation, while the film-coating technique diminishes the 
number of drying steps compared to those needed in sugar-coating. This is beneficial 
because temperature can lead to the melting of cyclophosphamide and to its 
conversion to a metastable phase, as already mentioned.  
Finally, the presented formulation is much simpler, what can significantly reduce the 
length and complexity of the traditional sugar-coating process.  
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6.  CONCLUSIONS 
– Cyclophosphamide has been used as an antineoplastic drug in a broad range 
of cancers for quite a long time. This explains the fact that it is marketed under 
different names by different laboratories around the globe, either as a brand 
name drug or, most commonly, as a generic. 
– Cyclophosphamide is a pro-drug with a high oral bioavailability. In addition, 
when administered orally, the AUC of its active metabolite is similar to that 
obtained with intravenous administration, Because of this, oral administration of 
cyclophosphamide is equivalent to intravenous administration from a 
pharmacokinetic point of view.  
– From the reduced stability of cyclophosphamide under certain conditions, 
especially in aqueous solution and at high temperatures, some conclusions can 
be elucidated:  
 The existence of a commercially available oral liquid formulation of 
cyclophosphamide would represent a major contribution to certain 
patients. However, it is reasonable to assume that simple syrups will 
continue to be prepared extemporaneously from powder for injection due 
to cyclophosphamide instability in aqueous solution.  
 Cyclophosphamide tablets can be protected from moisture, light, 
temperature, oxidation, etc. by applying a coating over the tablet core. 
Hence, available cyclophosphamide tablets are sugar-coated.   
 The traditional sugar-coating method provides excellent coatings. 
However, a part from being tedious, time-consuming and expensive, it 
requires important amounts of water and several drying stages. 
Utilization of such processes is controversial when the active ingredient 
is unstable in aqueous solution, sensitive to moisture or prone to 
degradation when heated. Thus, sugar-coating, as well as other 
manufacturing processes that might compromise the stability of the 
active ingredient, should be replaced with procedures that avoid water 
and drying at high temperatures.    
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 The proposed formulation, consisting of sorbitol film-coated tablets 
obtained by direct compression of the tablet cores followed by coverage 
with the film-coating technique, seems a good alternative for preserving 
cyclophosphamide stability during the manufacturing of the medication. 
Nevertheless, the formulation presented in this project is only a first 
approach to the development of cyclophosphamide sorbitol film-coated 
coated tablets. Consequently, several laboratory studies and quality 
control testing should be conducted in order to confirm the viability of the 
formulation and to establish a detailed manufacturing scheme that led to 
the optimal results.   
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